SL 0101-1
| Code | Size | Price |
|---|
| TAR-T16896-10mg | 10mg | £1,595.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
SL 0101-1 is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase inhibitor (IC50: 89 nM). It shows proliferation inhibition in human breast cancer cell line MCF-7 and produces a cell cycle block in G1 phase.
CAS:
77307-50-7
Formula:
C25H24O12
Molecular Weight:
516.455
Purity:
0.98
SMILES:
C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)cc2)[C@H](O)[C@H](OC(C)=O)[C@H]1OC(C)=O
References
1. Smith JA, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005 Feb 1;65(3):1027-34.